FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference

/in

Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD Heidelberg, Germany – 17 February 2026 – FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression […]

Read more

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin® at ESGO 2026

/in

9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose Oslo, Norway, 17 February 2026 – Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will present […]

Read more

Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer

/in

Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinic Reflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead candidate NTP464, which is progressing towards IND enabling studies  Oxford, UK, 16 February 2026 – Nucleome Therapeutics […]

Read more

Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026

/in

Oslo, Norway, 16 February 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is pleased to invite investors, analysts, and stakeholders to a live webcast event at 9:30 AM CET on Thursday, 26 February 2026. Second half […]

Read more

AmacaThera Named Life Sciences Ontario Emerging Company of the Year

/in

Recognition of AmacaThera’s leadership and landmark agreement with Pacira BioSciences for its long‑acting, opioid‑sparing anesthetic in post‑operative pain management Progressing AMT-143 to Phase 2 clinical development in 2026 Toronto, Ontario – February 11, 2026 — AmacaThera, a leading developer of next-generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a […]

Read more
© Optimum Strategic Communications.